Citi Downgrades Ultragenyx Pharma (RARE) to Sell

Citi downgraded Ultragenyx Pharma (NASDAQ: RARE) from Neutral to Sell.

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $82.06 yesterday.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Raised to $83 at Canaccord
• Goldman Sachs Downgrades Kuaishou Technology (1024:HK) to Neutral
• Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)